PHASeR Project Will Be Among First US Government Programs to Assess Clinical and Economic Potential of Evolving Approach to Health Care
WASHINGTON (March 12, 2019)
The Personalized Medicine Coalition (PMC) today congratulates Sanford Health and the U.S. Department of Veterans Affairs (VA) on a partnership announced this morning that will explore how genetic testing may make the VA’s health care system more effective and efficient by identifying which medications are most appropriate for each patient. The partnership will be among the first the U.S. government has undertaken to assess the potential of personalized medicine, an evolving field in which physicians use diagnostic tests to guide medical treatments.
Through the PHarmacogenomics Action for Cancer SuRvivorship (PHASeR) project, which was made possible by a $25 million gift from Mr. Denny Sanford and a matching fundraising effort at Sanford Health, the nonprofit health care provider will sponsor genetic testing and results interpretation for 250,000 U.S. veterans receiving care at the VA by 2020. The institutions will make the data from PHASeR available to researchers at the VA, who will use it to further our understanding of how genomic data can be used to improve patient care and make better use of health care resources.
“By investing in a program that is among the first to explore the clinical and economic value of personalized medicine on such a large scale, Sanford Health and the VA are leading the way toward a new era in health care that holds tremendous promise for patients and health systems,” said PMC President Edward Abrahams.
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.